What is Shanghai Fosun Pharmaceutical (Group) Co Accounts Receivable?
Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Shanghai Fosun Pharmaceutical (Group) Co's accounts receivables for the quarter that ended in Dec. 2024 was ¥7,952 Mil.
Accounts receivable can be measured by Days Sales Outstanding.
Shanghai Fosun Pharmaceutical (Group) Co's Days Sales Outstanding for the quarter that ended in Dec. 2024 was 71.45.
In Ben Graham's calculation of Net-Net Working Capital, accounts receivable are only considered to be worth 75% of book value. Shanghai Fosun Pharmaceutical (Group) Co's Net-Net Working Capital per share for the quarter that ended in Dec. 2024 was ¥-16.65.
Shanghai Fosun Pharmaceutical (Group) Co Accounts Receivable Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Shanghai Fosun Pharmaceutical (Group) Co Accounts Receivable Chart
Shanghai Fosun Pharmaceutical (Group) Co Annual Data
Shanghai Fosun Pharmaceutical (Group) Co Accounts Receivable Calculation
Accounts Receivable is money owed to a business by customers and shown on its Balance Sheet as an asset.
Shanghai Fosun Pharmaceutical (Group) Co Accounts Receivable Explanation
1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.
Shanghai Fosun Pharmaceutical (Group) Co's Days Sales Outstanding for the quarter that ended in Dec. 2024 is calculated as:
2. In Ben Graham's calculation of Net-Net Working Capital (NNWC), Shanghai Fosun Pharmaceutical (Group) Co's accounts receivable are only considered to be worth 75% of book value:
Shanghai Fosun Pharmaceutical (Group) Co's Net-Net Working Capital Per Share for the quarter that ended in Dec. 2024 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net receivables tells us a great deal about the different competitors in the same industry. In competitive industries, some attempt to gain advantage by offering better credit terms, causing increase in sales and receivables.
If company consistently shows lower % Net receivables to gross sales than competitors, then it usually has some kind of competitive advantage which requires further digging.
Average Days Sales Outstanding is a good indicator for measuring a company's sales channel and customers. A company may book great revenue and earnings growth but never receive payment from their customers. This may force a write-off in the future and depress future earnings.
Shanghai Fosun Pharmaceutical (Group) Co Accounts Receivable Related Terms
Thank you for viewing the detailed overview of Shanghai Fosun Pharmaceutical (Group) Co's Accounts Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.
Shanghai Fosun Pharmaceutical (Group) Co Business Description
Shanghai Fosun Pharmaceutical (Group) Co Ltd is engaged in the development, manufacture, and sale of pharmaceutical products and medical equipment, the import and export of medical equipment, and the provision of related and other consulting services and investment management. Its business segments are Pharmaceutical manufacturing, Healthcare Services, Medical devices, and medical diagnosis. It generates the majority of its revenue from the Pharmaceutical manufacturing segment. The company considers merger and acquisition investment as a potential component of its operational growth for expanding its research, development, manufacturing, and marketing capabilities. Its geographic areas are the Chinese mainland, Regions outside the Chinese mainland, and other countries.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
SHSE:600196 has been successfully added to your 